Jonathan Smith, PhD spotlights five private companies pushing the boundaries of microbiome-based therapeutics — from tackling C. difficile to boosting cancer treatments. As sequencing costs drop and science uncovers deeper gut-health links, these startups are developing precise, standardized alternatives to fecal microbiota transplants and exploring applications in immunology, oncology, and chronic disease.
Keep Reading
Add A Comment